CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy
Cancer Chemotherapy and Pharmacology · 17.08.2026 · 96 (1)
DOI: 10.1007/s00280-026-04941-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 17.08.2026. Verfasst von Guangmao Mu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou, China. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Immunoconjugates, Interferon-alpha, Cell Adhesion Molecules. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: CUB domain-containing protein 1 (CDCP1) is an emerging tumor-associated surface antigen broadly expressed in solid tumors and linked to poor prognosis, making it an attractive target for selective therapeutic delivery. We evaluated CDCP1 as a platform for two distinct therapeutic modalities: an antibody-drug conjugate (ADC) for cytotoxic payload delivery and an immunocytokine for targeted delivery of interferon-α2b (IFNα2b). METHODS: Novel humanized anti-CDCP1 monoclonal antibodies were generated and characterized for binding to recombinant and cell-surface CDCP1. CDCP1 expression in tumor cells and xenografts was assessed by flow cytometry and immunohistochemistry. CDCP1-targeted ADCs and CDCP1-targeted IFNα2b fusion proteins, including attenuated IFNα2b variants, were evaluated for in vitro cytotoxicity and in vivo antitumor activity in multiple solid tumor xenograft models. A murine cross-reactive anti-CDCP1 ADC was further assessed in an acute mouse toxicity study. RESULTS: CDCP1 was broadly expressed across multiple solid tumor cell lines and xenografts. CDCP1-targeted ADCs mediated potent, target-dependent cytotoxicity in vitro, and MMAE-conjugated ADCs showed robust antitumor activity in pancreatic, lung, breast, and colon xenograft models, with tumor growth inhibition up to 90%. Antibodies recognizing the proteolyzed amino-terminal region of CDCP1 also retained in vivo activity. The murine cross-reactive ADC was well tolerated in an acute toxicity study. CDCP1-targeted IFNα2b fusion proteins displayed markedly enhanced potency against CDCP1-positive tumor cells versus a non-targeted control, and IFNα2b attenuation enabled tunable cytokine activity. In a human PBMC-supported BxPC-3 model, a CDCP1-targeted IFNα2b immunocytokine achieved significant tumor growth inhibition. CONCLUSION: These findings established CDCP1 as a versatile therapeutic target and supported further development of parallel CDCP1-targeted ADC and immunocytokine strategies for solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou, China.
- Tavotek Biotherapeutics Inc., 727 Norristown Rd., Bldg. 3, Ste 101, Ambler, PA, 19002, USA.
- Tavotek Biotherapeutics Inc., 727 Norristown Rd., Bldg. 3, Ste 101, Ambler, PA, 19002, USA. di.zhang@tavotek.com.
Zitieren
APA
Mu, G., Yu, M., Zhou, F., Bi, H., Zha, Z., Huang, S., Jin, Y., Han, C., Chiu, M. L., & Zhang, D. (2026). CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04941-6
Vancouver
Mu G, Yu M, Zhou F, Bi H, Zha Z, Huang S, et al. CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04941-6
BibTeX
@article{Mu2026,
author = {Mu, Guangmao and Yu, Mingcan and Zhou, Fulai and Bi, Honglei and Zha, Zhengxia and Huang, Sheng and Jin, Ying and Han, Chao and Chiu, Mark L and Zhang, Di},
title = {CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04941-6}
}
EUVIMED